Fairmount Funds Management as of June 30, 2026
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 12 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Oruka Therapeutics (ORKA) | 23.3 | $353M | 3.7M | 95.17 | |
| Dianthus Therapeutics (DNTH) | 16.3 | $247M | 2.5M | 97.48 | |
| Damora Therapeutics Com New (DMRA) | 15.0 | $227M | 8.7M | 26.01 | |
| Cogent Biosciences (COGT) | 14.1 | $213M | 5.5M | 38.70 | |
| Jade Biosciences Com New (JBIO) | 6.7 | $101M | 4.6M | 22.22 | |
| Enliven Therapeutics (ELVN) | 6.2 | $94M | 1.9M | 50.75 | |
| Miragen Therapeutics (VRDN) | 6.2 | $94M | 5.1M | 18.37 | |
| Zenas Biopharma (ZBIO) | 4.0 | $60M | 2.4M | 25.38 | |
| Crescent Biopharma (CBIO) | 3.3 | $50M | 2.7M | 18.00 | |
| Apogee Therapeutics (APGE) | 2.6 | $40M | 299k | 132.73 | |
| Faeth Therapeutics Com New (FTH) | 1.2 | $18M | 722k | 25.00 | |
| Inhibikase Therapeutics Com New (IKT) | 1.2 | $18M | 8.6M | 2.03 |
